Eli Lilly reported weaker results for the latest quarter than analysts ... In stock markets abroad, indexes were mostly lower ...

Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings ... The approval of Kisunla in Japan and Great Britain for the treatment of early symptomatic Alzheimer's disease.

Eli Lilly just got approval in the U.K. to market ... in the U.S and regulators in Japan. The U.K.'s regulators concurred with the results of clinical trials suggesting that the drug is somewhat ...

Everyone knows that big pharma companies like Eli Lilly (NYSE: LLY) need to get regulators to agree that their medicines are safe and effective before they can make any money. But regulators aren't ...

Everyone knows that big pharma companies like Eli Lilly (NYSE: LLY ... in the U.S and regulators in Japan. The U.K.'s regulators concurred with the results of clinical trials suggesting that ...

Eli Lilly reported weaker results for the latest ... indexes were mostly lower in Europe and Asia despite a 1% rise for Japan’s Nikkei 225 as the Bank of Japan began a two-day policy meeting.

Eli Lilly reported weaker results for the latest ... indexes were mostly lower in Europe and Asia despite a 1% rise for Japan’s Nikkei 225 as the Bank of Japan began a two-day policy meeting.